Key result
Pro-hypertrophic agonists trigger rapid MRTFA nuclear shuttling via actin polymerization and RhoA/PI3K pathways.
Why the study?
Most knowledge on SRF-MRTF-Actin axis regulation was obtained in non-muscle and smooth muscle cells, leaving its role and nucleocytoplasmic shuttling in cardiomyocytes unclear.
Highlights a central role for the SRF-MRTFA-actin axis regulated by the RhoA/ROCK and PI3K/Akt pathways in cardiac remodeling, offering mechanistic insights into cardiomyocyte hypertrophy.
Supports further investigation of the SRF-MRTF-A-actin axis in remodeling; does not support clinical translation.
Myocardin-related transcription factors (MRTFs) play a central role in the regulation of actin expression and cytoskeletal dynamics that are controlled by Rho GTPases. SRF is a ubiquitous transcription factor strongly expressed in muscular tissues. The depletion of SRF in the adult mouse heart leads to severe dilated cardiomyopathy associated with the down-regulation of target genes encoding sarcomeric proteins including α-cardiac actin. The regulatory triad, composed of SRF, its cofactor MRTFA and actin, plays a major role in the coordination of the nuclear transcriptional response to adapt actin filament dynamics associated with changes in cell shape, and contractile and migratory activities. Most of the knowledge on the regulation of the SRF-MRTF-Actin axis has been obtained in non-muscle cells with α-actin and smooth muscle cells with α-smooth actin. Here, we visualized for the first time by a time-lapse video, the nucleocytoplasmic shuttling of MRTFA induced by serum or pro-hypertrophic agonists such as angiotensin II, phenylephrine and endothelin-1, using an MRTFA-GFP adenovirus in cultures of neonatal rat cardiomyocytes. We showed that an inhibitor of the RhoA/ROCK signaling pathway leads to an α-cardiac actin polymerization disruption and inhibition of MRTFA nucleocytoplasmic shuttling. Moreover, inhibition of the PI3K/Akt signaling pathway also prevents the entry of MRTFA into the nuclei. Our findings point out a central role of the SRF-MRTFA-actin axis in cardiac remodeling.
No takes yet. Share an insight, caveat, or question.
Gorey et al. (2022) studied Cardiac remodeling / Hypertrophy (preclinical model). Serum or pro-hypertrophic agonists (angiotensin II, phenylephrine, endothelin-1) vs. Serum-free baseline conditions was evaluated on Nucleocytoplasmic shuttling of MRTFA-GFP and actin dynamics. Pro-hypertrophic agonists and serum induced the rapid nucleocytoplasmic shuttling of MRTFA in cardiomyocytes, which was linked to increased actin polymerization and blocked by RhoA/ROCK and PI3K/Akt pathway inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: